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CONCLUSIONS: This exploratory analysis suggests that use of a broader range of
metrics to assess and benchmark value across tumor types may be needed to
appropriately inform decision-makers looking to maximize clinical benefit to pa-
tients while managing constrained resources.
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OBJECTIVES: Unlike randomized clinical trials (RCTs), prospective observational
studies typically address objectives rather than test specific hypotheses. Neverthe-
less, a minimum sample size is required to allow for adequate exploration of the
objectives, and estimation of sample size is an important part of the planning
process for these studies. Sample size estimation for observational studies is more
complex than sample size calculation for RCTs; subgroup analyses and modeling
are to be expected in observational studies, and these analysis methods may re-
quire more assumptions and larger sample sizes. At the same time, sample sizes
must not be so large as to raise concern that the study includes an unnecessarily
high number of sites and patients. This is particularly true for product registries
where a specific product is being observed. METHODS: This poster will provide
examples/case studies of sample size estimations performed for a variety of pro-
spective observational studies and objectives. These case studies will focus on the
following METHODS: 1) Incorporation of planned propensity score matching to
support comparisons of cohorts or subgroups; 2) Investigation of factors that influ-
ence outcomes within subgroups; 3) Estimation expressed as number of person-
years rather than persons; and 4) Re-estimation of sample size based on interim
results. RESULTS AND CONCLUSIONS: These methods illustrate the difference
between sample size estimation in prospective observational studies and sample
size calculation in randomized clinical trials.
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OBJECTIVES: Economic evaluation (EE) estimates for individual centres in multi-
centre randomized controlled trials (RCTs) can differ significantly from the trial-
wide result. The existing methods addressing the generalisability of EE results from
RCTs (e.g. bivariate hierarchical modelling) assume that the recruiting centres are
representative for their jurisdictions, but this assumption has not been generally
verified. No explicit method of selecting centres and their recommended sample
sizes has been described, despite having been suggested in the literature.
METHODS: The working hypothesis is that transparent centre selection is a crucial
step in assessing the generalisability of EE results from RCTs. Two questions arise:
1) What criteria underpin the current practice of selecting centres for RCT-based
EEs? and 2) Can a valid quantitative algorithm be formulated to assist the centre
selection process at the trial design stage? RESULTS: First, the use of modelling-
based methods addressing generalisability has to be supported by evidence that
centres are representative for the jurisdiction under scrutiny. There is, thus, a need
to assess the current practice of selecting centres for RCT-based EEs. Second, a
quantitative methodology for purposively selecting centres for RCTs coupled with
EEs has to be devised in order to underpin an objective centre selection process.
The proposed operational measure is a generalisability index (GIx) which aggre-
gates relevant generic and intervention-specific covariates and can be formulated
at both jurisdiction and centre-level. The GIx can be validated against centre-level
cost-effectiveness estimates.CONCLUSIONS:A successfully validated GIx will pro-
vide evidence towards the legitimate use of existing generalisability techniques.
The GIx will allow an objective generalisability assessment for centres that did not
participate in the RCT. Describing the rationale for centre selection must become a
standalone item in reporting checklists for RCTs and EEs. Furthermore, such a
methodology will bridge policy and research by correlating jurisdictional interests
with RCT design.
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OBJECTIVES: In any assessment to facilitate decision making to allocate limited
funding across multiple innovations, the relative value of clinical outcomes or cost
containment depends upon preferences. In the case of allocating funds across a
portfolio of interventions, one could maximise cases-, hospitalizations-, or deaths-
avoided; and/or minimize costs from a health care payer or societal perspective.
The optimal mix of innovations to reach the preferred target can be investigated by
applying operational research modelling. However, a composite outcome is re-
quired in order to maximise multiple endpoints consecutively depending upon
preferences for different endpoints. METHODS: An optimization model was devel-
oped in Microsoft Excel® using the solver function to evaluate the optimal mix of
vaccines to implement within a portfolio, in order to avoid specific clinical out-
comes (GP-visits, hospitalisations, deaths) or maximise QALYs gained within spe-
cific constraints including budget. A composite endpoint was developed to take
into account different endpoints, clinical and cost, weighted according to prefer-
ences defined by the assessor. The composite endpoint was used as the objective
function. RESULTS: Depending upon the preference weights defined when deter-
mining the composite endpoint, the allocation of resources across a portfolio of
several vaccines resulted in different recommendations. If deaths-avoided was
weighted highest then the model would optimize on elderly influenza vaccination,
adolescent HPV and infant pneumococcal vaccines. If cases-avoided was the high-
est preference then varicella, rotavirus and pertussis vaccines were recommended.
If cost-offsets from a payer perspective were maximised then the recommendation
would be to first implement adolescent HPV, elderly influenza and rotavirus vac-
cination. The combination of preferences to avoid mortality and/or morbidity
and/or maximize cost offsets resulted in the recommendation to implement dif-
ferent vaccines from the portfolio.CONCLUSIONS:The use of a composite measure
and operational research modelling provides a tool to facilitate resource allocation
across a portfolio of interventions depending upon decision-maker preferences.
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OBJECTIVES: Developers of patient reported outcome (PRO) measures are often
involved in the translation of their measures into other languages, and they pro-
vide valuable guidance by reviewing concept elaboration and back translation re-
view documents and participating in harmonisation meetings. METHODS: How-
ever, many of the translation problems that they help resolve are due to difficulties
in translating concepts in the measure that are either culturally bound or idiomatic
to the source language, and these are features that might be addressed more ef-
fectively at an earlier stage. RESULTS: The developer can have a positive impact on
future translations right from the onset by considering the ‘translatability’ of con-
cepts when they are developing their conceptual model and generating their item
pool, thereby aiming to create a measure which can be translated more accurately.
CONCLUSIONS: We will examine common linguistic and cultural features which
may make measures difficult to translate, and how developers can avoid these to
help create global PRO measures that can be applied to all cultures and be admin-
istered in global clinical trials and health research.
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OBJECTIVES: Recent work has suggested that interventions’ cost-effectiveness
should be assessed over their entire lifetime of implementation, not just over the
period of use for a single cohort as typically modelled (Hoyle and Anderson, Med-
ical Decision Making, 2010; Hoyle, PharmacoEconomics, 2011). Such lifetime mod-
elling can capture changes in costs and effects over time. These changes in costs
and effects can result from price changes, disease dynamics or the application of
differential discounting of costs and health effects. METHODS: Suggesting cost-
effectiveness be assessed over an intervention’s complete lifetime carries assump-
tions regarding the nature of the decision problem in healthcare resource alloca-
tion. In particular, it suggests resources be allocated on the basis of the total cost-
effectiveness over all periods in which it is implemented. This lifetime perspective
can conflict with the alternative perspective that resources be allocated on the
basis of relative cost-effectiveness within each given period. We discuss a number
of simple theoretical examples in which the rank ordering of cost-effectiveness of
two interventions is different under the two perspectives. The examples include
when the prices of interventions trend and have different expected lifetimes, when
differential discounting is applied in certain circumstances, or simply when the
price of only one intervention falls following patent expiry. RESULTS: These exam-
ples prompt us to consider which perspective is more appropriate. We argue that as
health care resource allocation is an ongoing, repeated resource allocation prob-
lem, not one over a finite horizon, that the lifetime perspective is not appropriate.
CONCLUSION: Advances in decision analytic modelling need to carefully reflect the
actual nature of policy choices. The per-period perspective appears more appro-
priate to healthcare resource allocation problems than the total implementation
lifetime perspective. However, the actual resource allocation process is likely to
more complex than either perspective alone might suggest.
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COMPARISON OF RECONCILIATION AND REVIEW METHODOLOGIES FOR THE
TRANSLATION OF PATIENT REPORTED OUTCOME (PRO) MEASURES
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PharmaQuest Ltd, Banbury, Oxfordshire, UK Objective: The translation of patient reported
outcome (PRO) measures typically involves two key stages where the translation is created and
refined.
METHODS: The first is the reconciliation of two independent translations by an
in-country investigator (a lead translator). The second is the back translation re-
view - the reconciled translation is translated back into English and the project
manager reviews the English translation(s) against the source text, then the trans-
lation is refined through discussion between the project manager and the investi-
gator. Both stages are conducted via email, and the back translation review report
is usually reviewed by the instrument developer once all issues have been ad-
dressed. We will present an alternative methodology whereby the reconciliation
and back translation review are conducted through live conversations (in telecon-
ferences or otherwise) involving forward translators and the instrument developer.
RESULTS:We will compare these two processes in terms of the types of discussion
A432 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
